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ABSTRACT 
The purpose of this work was to design and evaluate matrix type transdermal patches of Tizanidine hydrochloride using Hypromellose (HPMC 
E15) as polymer, dibutyl phthalate as plasticizer and citral as permeation enhancer. The DSC and FTIR results showed the compatibility of the 
excipients with the drug. These transdermal drug delivery systems were characterized for their thickness, folding endurance, content uniformity, 
tensile strength and in-vitro release studies of the drug from the polymeric matrix. In-vitro release studies and ex-vivo permeation were carried 
out with modified Franz diffusion cell using pH 5.8 & pH 7.4 phosphate buffers as receptor medium and it showed controlled release of drug. The 
results suggest that the formulation of TIZ may be useful in the development of a therapeutic system to deliver TIZ across the skin for a 
prolonged period, i.e. 24 hr. 
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INTRODUCTION 
Transdermal therapeutic system are defined as 'self-
contained' discrete dosage forms which, when applied to the 
intact skin, deliver the drug(s), through the skin, at a 
controlled rate to the systemic circulation. Transdermal drug 
delivery systems (TDDS) offer many advantages such as 
reduced side effects, elimination of first-pass metabolism 
and improved patient compliance.  Transdermal drug 
delivery system is used for delivery of drugs with small 
molecular size, short half-life, low oral bioavailability and 
low dose, etc. In recent times, transdermal patches are 
become most acceptable approach for patients. Several drugs 
were administered through transdermal route by matrix-
type transdermal patches which include aceclofenac, 
dexamethasone, terbutaline sulphate, atenolol, diltiazem, etc. 
Present day, transdermal patches are applied in several 
therapeutic regions like smoking cessation, pain 
management, hormone replacement and treatment of heart 
disease1-5. Tizanidine hydrochloride is a smooth muscle 
relaxant with half life of 2.54 hrs. It exhibits first-pass 
metabolism, which leads to poor bioavailability i.e.<40%. 
Very few studies were reported on transdermal patches 
using tizanidine hydrochloride. The  objective of the present 
study was to develop and evaluate transdermal delivery 
systems of TIZ for invitro release studies, ex-vivo permeation 
studies and mechanical properties.  
MATERIALS 
Tizanidine hydrochloride obtained as a gift sample from 
Yarrow chem Ltd. HPMC E15 was supplied by BMR 
chemicals, HYD. Potassium dihydrogen ortho phosphate, 
Sodium hydroxide, Methanol, Dichloromethane and dibutyl 
phthalate were supplied by Merck Ltd, Mumbai. Citral were 
purchased from Merck Ltd. Dialysis membrane was supplied 
by Hi Media Laboratories Pvt Ltd, Mumbai. 
Methodology: 
Drug polymer interaction studies 
To study the possible interaction between Tizanidine HCl 
and polymeric materials of the patches, Differential scanning 
calorimetry(DSC, Perkin Elmer 4000) and FTIR (KBR pellet 
method) was carried out on pure drug and drug-excipient 
physical mixture. 
Preparation of transdermal patches  
The preparation of transdermal patches of TIZ was carried 
out by following solvent casting technique. Weighed 
quantities of polymer (Table I) Hydroxy propyl methyl 
cellulose (HPMC E 15 LV), were taken in a boiling tube. 
About 20 ml of solvent mixture of dichloromethane: 
methanol (1:1) was added and vortexed. Sufficient care was 
taken to prevent the formation of lumps. The boiling tube 
was set-aside for 6 hours to allow the polymer to swell. After 
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swelling dibutyl phthalate as a plasticizer 15-17%v/w (of 
dry polymer weight), permeation enhancer and weighed 
amount of drug was added to this polymeric mixture and 
mixed well. It was set-aside for sometime 10-15mins to 
exclude any entrapped air and was then transferred into a 
previously cleaned Anumbra Petri plate (72.3 sq cm). Drying 
of these patches were carried out at room temperature for 
overnight and then the polymeric films formed were 
removed carefully, placed in a vacuum oven and vacuum was 
applied for 8-12hrs to remove traces of solvent if any. They 
were stored in a desiccator till the evaluation tests were 
performed. The entire film was cut into patches of 4.9cm2 
(12). 
Table I: Composition of TIZ transdermal patches 
Formulation 
code 
Drug 
(mg) 
HPMC E15 
(mg) 
Citral 
(%) 
T1 30 600 - 
T2 30 800 - 
T3 30 1000 - 
T4 30 1200 - 
T5 30 1000 12 
T6 30 1000 14 
T7 30 1000 16 
Note:  17% v/w Dibutyl phthallate to the total polymer 
weight, incorporated as Plasticizer. 
Each patch (4.9 cm2) contains 2mg of TIZ. 20ml 
dichloromethane:methanol(1:1) 
 
Evaluation Parameters 
Thickness 
The thickness of the film was measured at 5 different points 
using screw gauge. For each formulation, three selected films 
were used and average thickness was recorded. 
Weight variation 
Three films from each batch of an area of 4.9 cm2 were 
weighed individually and the average weight was calculated. 
Folding endurance 
Folding endurance of the patch was determined manually by 
repeatedly folding a small strip of the medicated patch at 
same place until it breaks. The number of times the strip 
could be folded at the same place without breaking gave the 
folding endurance number. 
Drug content  
Films from each formulation were taken, cut into small 
pieces (4.9 cm2), and were allowed to dissolve in a 100 ml 
phosphate buffer and kept on magnetic stirrer for 24 hrs. 
The solution was filtered using whatmann filter paper & 
diluted suitably and the absorbance of the solution was 
measured using UV-visible spectrophotometer at 235 nm 
against blank. 
In-vitro release studies 
The drug release studies from TIZ transdermal patches were 
performed using Franz diffusion cells. Commercially 
available water impermeable adhesive backup membrane 
was placed over the patches (4.9 cm2). Then the transdermal 
patch was placed over a dialysis membrane (Himedia MolWt 
5000) and sandwiched between the two compartments and 
fixed tightly using clamps. The whole set up was placed on 
magnetic stirrer. Samples (2 ml) were collected up to 24 hrs. 
Analysis was carried out using UV-Vis spectrophotometer. 
Phosphate buffer pH 5.8 (15 ml) was used as release media. 
The study was conducted at 32 ±0.5oC at a speed of 500 rpm. 
The analysis was done at 235 nm against phosphate buffer 
pH 5.8 as blank. Mathematical expressions, zero order4, First 
order14 and Higuchi model were applied to analyze the 
release mechanism from the transdermal patches. 
Preparation of rat abdominal skin 
Wistar rats weighing 230-250 gm were sacrificed using 
anaesthetic ether (IAEC/23/Ucpsc/KU/2018). The hair of 
test animals were carefully trimmed short (<2 mm) with a 
pair of scissors and the full thickness skin was removed from 
the abdominal region. The epidermis was prepared 
surgically by heat separation technique, which involved 
soaking the entire abdominal skin in water at 60oC for 45 
sec, followed by careful removal of the epidermis. The 
epidermis was washed with water and used for ex-vivo 
permeability studies. 
Ex-vivo permeation studies 
Franz diffusion cell with a surface area of 4.9 cm2 was used 
for ex-vivo permeation studies. The rat skin was mounted 
between the compartments of the diffusion cell with stratum 
corneum facing the donor compartment. The stratum 
corneum side of the skin was kept in intimate contact with 
the release surface of the TDDS under test. The receiver 
phase 15ml of phosphate buffer saline (PBS) pH 7.4, stirred 
at 500 rpm on a magnetic stirrer; the whole assembly was 
kept at 37 ± 0.5oC. The amount of drug permeated was 
determined by removing 2ml of sample at appropriate time 
intervals up to 24 hr, the volume was replenished with an 
equal volume of phosphate buffer saline pH 7.4. The 
absorbance was measured at 235 nm 
spectrophotometrically. Cumulative amounts of drug 
permeated in μg/cm2 were calculated and plotted against 
time. Drug flux (μg/hr/cm2) at steady state was calculated by 
dividing the slope of the linear portion of the curve by the 
area of the exposed skin surface (4.9 cm2)11 and the 
permeability coefficient was deduced by dividing the flux by 
initial drug load12. 
The target flux is calculated using the following equation. 
                                                   CSS ClT BW 
                                   JTarget = ------------------- 
                                                          A 
A represents the surface area of the transdermal patch (i.e 
4.9 cm2); BW, the standard human body weight of 60 kg; Css 
the TIZ concentration at the therapeutic level (0.015µg/ml) 
and the ClT the total clearance (0.504L/hr/kg), the calculated 
target flux value for TIZ was 15.42µg/hr/cm2. 
Moisture absorption study 
The films were weighed accurately and placed in a desiccator 
containing 100ml saturated solution of aluminum chloride 
(79.50% RH). After 3 days, the films were taken out and 
weighed, the percentage of moisture uptake was calculated 
as the difference between final and initial weight with 
respect to initial weight9. 
Moisture content 
The patches were weighed and kept in a desiccator 
containing calcium chloride at 40oC for 24 hr. The final 
weight was noted when there was no further change in the 
weight of patch. The percentage of moisture content was 
calculated as a difference between initial and final weight 
with respect to initial weight5. 
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Measurement of mechanical properties 
Mechanical properties of the fabricated films were evaluated 
using a microprocessor based advanced force gauze 
equipped with a motorized test stand (Ultra Test, Mecmesin, 
West Sussex, and UK), equipped with 25 kg load cell. The 
Tensile strength (T.S) was measured using the film strip 
(60×10mm) free from air bubbles or any physical 
imperfections. The film strip (60 × 10mm) was held between 
two clamps positioned at a distance of 3 cm. During 
measurement, the top clamp at a rate of 2 mm s-1pulled the 
strips to a distance till the film broke. The force required to 
break the film was consider as a tensile strength and it was 
calculated as kg/mm2.  
                                      Force required to break patch (kg) 
  Tensile strength = 
                                      Cross-sectional area of patch (mm2) 
RESULTS AND DISCUSSION 
DSC study: The DSC curve of tizanidine hydrochloride 
showed a single sharp endothermic peak at 279ºC 
corresponding to its melting point 280ºC. In optimized 
formulation, endothermic peak of drug was well preserved 
with slight changes in terms of shifting towards the lower 
temperature, 278ºC. 
 
 
Figure 1: DSC thermogram of pure drug                 Figure 2:DSC thermogram of drug + polymer 
 
FTIR spectra: The IR spectral analysis of TIZ HCl alone 
showed that the principal peaks were observed at wave 
numbers of 1635.69, 2931.9, 3242.95. In the IR spectra of the 
physical mixture of TIZ HCl and HPMC E15 the principal 
peaks were observed at 1635.61, 2933.93, 3443.05. 
However, some additional peaks were observed with 
physical mixtures, which could be due to the presence of 
polymers. These results suggest that there is no interaction 
between the drug and polymers used in the present study.  
 
Table II. Comparison of the Peaks of Functional Groups Observed in FTIR Spectra 
    
Functional group   C=N Stretch  C-H Stretch  N-H Stretch 
Tizanidine HCl  1635.69  2931.90  3242.95 
 
Tizanidine HCl with HPMC E15  1635.61  2933.93  3443.05 
 
 
Figure 3: FTIR spectra of pure TIZ HCl 
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Figure 4: FTIR Graph of Pure Tizanidine HCL With HPMC 
 
Moisture absorption and moisture content studies: 
The moisture content in the patches is ranged from 4.2 ± 
0.23 to 6.0 ± 0.24%. The moisture absorption in the 
formulations is ranged from 5.4 ± 0.35 to 6.8 ± 0.33%. The 
results revealed that the moisture absorption and moisture 
content was found to increase with increasing concentration 
of hydrophilic polymer (HPMC). The low moisture 
absorption protects the transdermal films from microbial 
contamination and small moisture content prevents the films 
from becoming brittle. 
Mechanical Properties 
The tensile testing gives an indication of the strength and 
elasticity of the film, reflected by the parameters, tensile 
strength (TS) and elastic modulus (EM) and elongation at 
break (E/B). A soft and weak polymer is characterized by a 
low TS, EM and E/B; a hard and brittle polymer is defined by 
a moderate TS, high EM and low E/B; a soft and tough 
polymer is characterized by a moderate TS, low EM and high 
E/B; where as a hard and tough polymer is characterized by 
a high TS, EM and E/B. The results of mechanical properties 
are shown in Table III. Formulation T3 and T4 exhibited 
greater values of tensile strength  (1.63 ± 0.22 kg/mm2 and 
1.72 ± 0.25 kg/mm2 respectively). The results revealed that 
as the concentration of HPMC increased, the tensile strength 
was found to be increased. These observations indicate that 
formulation T3 patches were found to be strong, not brittle 
and flexible, T4 patches were found to be strong but were 
brittle and not flexible. 
 
Table III: Physico chemical evaluation of different formulations 
Formula-
tion code 
Thickness 
(mm) 
Weight 
variation  
(mg) 
Drug content 
(mg) 
Moisture 
content 
(%) 
Moisture 
absorption 
(%) 
Tensile 
strength 
(kg/mm2) 
T1 0.34±0.82 36.0±0.97 2.1±0.76 4.2±0.23 5.4±0.35 1.26±0.23 
T2 0.36±0.80 38.2±0.93 1.98±0.74 5.3±0.23 5.8±0.34 1.50±0.24 
T3 0.38±0.75 40.2±1.0 2.0±0.74 5.7±0.20 6.2±0.34 1.63±0.22 
T4 0.38±0.75 40.5±0.84 1.97±0.64 6.0±0.24 6.8±0.33 1.72±0.25 
T5 0.37±0.74 40.2±0.72 2.0±0.78 5.4±0.23 6.0±0.32 1.60±0.24 
T6 0.38±0.86 40.1±0.87 2.1±0.76 5.3±0.22 6.3±0.35 1.63±0.25 
T7 0.38±0.75 40.3±1.13 2.0±0.78 5.7±0.20 6.2±0.34 1.60±0.24 
Values represent mean ± SD (n=3). 
 
In-vitro release Studies 
 Formulation T3 exhibited greatest (53.7±3.23) percentage 
of drug release without citral. In the present study it was 
observed that as the concentrations of hydrophilic polymer 
(HPMC) increased in the formulations, the drug release rate 
increased substantially, however with a very nominal 
decrease in formulation T4 may be due to increase in the 
diffusional path length . 
The addition of citral  in different concentration to T3 
formulation (Table IV) tends to enhance the release rates 
(Fig 5). The description of dissolution profiles by a model 
function has been attempted using different kinetics (zero 
order, first order and Higuchi square-root model) and using 
the equation derived by Korsmeyer et al. 
Higuchi square route seemed to be the most appropriate 
model describing release kinetics from all patches 
(R2=0.8874). On the other hand n values (n<0.5) indicated 
that amount of released drug was by Fickian diffusion. 
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Table IV: in-vitro %cumulative drug release studies 
Time points 
(hrs) 
T5 (12%) T6 (14%) T7 (16%) 
0 0 0 0 
0.5 33.0±2.36 50.6±1.53 36.5±2.65 
1 34.1±2.58 54.9±1.09 40.1±2.3 
2 35.7±2.46 58.4±1.12 43.6±1.06 
4 38.5±2.03 65.1±1.86 56.1±1.73 
6 51.9±2.76 74.2±2.08 63.3±1.13 
8 58.0±1.94 80.9±2.05 66.3±1.07 
12 62.4±1.73 90.7±1.78 68.8±1.54 
24 74.5±1.58 101.8±1.54 78.75±2.20 
Values represent mean ± SD (n=3) 
 
 
Figure 5: Comparison of % cumulative drug release of 
TIZ HCl from formulations with 1000 mg HPMC E 15 with 
varied citral concentration, T5(12%), T6(14%),T7(16%) 
Ex-vivo permeation studies of formulations containing 
citral:  
The results of ex-vivo skin permeation of TIZ HCl from 
patches were shown in Fig (6). The cumulative amounts of 
drug permeated per square centimeter of patches through 
the rat abdominal skin when plotted against time, the 
permeation profiles of drug from  T6 seem to follow Zero 
order kinetics as it is evidenced by correlation coefficient 
(0.9903)and Higuchi’s equation (R2=0.9460), n values 
(0.823) indicated that amount of released drug was by non 
Fickian diffusion. As the concentration of citral increased, 
drug permeation increased by modifying solvent nature of 
stratum corneum and improves drug partition coefficient 
into tissue and further increase in concentration, permeation 
was decreased, this could be attributed to the interaction 
between citral & drug . The required flux was higher than the 
targeted flux (15.42 µg/hr/cm2) with formulation T6 (14% 
citral 16.06µg/hr/cm2), while T5 (12%) & T7 (16%) showed 
lower flux than targeted flux, thus T6 formulation was 
optimized. The results of drug permeation from transdermal 
patches of TIZ HCl through the rat abdominal skin confirmed 
that TIZ HCl was released from the formulation and 
permeated through the rat skin and hence could possibly 
permeate through the human skin. 
 
Table V: Ex-vivo skin permeation studies 
Time points 
(hrs) 
T5 
(µg/cm2) 
T6(µg/cm2) T7(µg/cm2) 
0 0 0 0 
0.5 63.3±12.5 73.09±10.1 72.9±7.25 
1 110±8.23 147.8±9.35 126±11.01 
2 172±11.57 245±8.12 200±11.25 
4 316±10.8 433±11.2 369±8.34 
6 526±15.2 633.8±8.08 580±12.65 
8 633±10.6 701±8.51 654±11.25 
12 847±15.7 1109±10.02 876±10.67 
24 1309±11.2 1905±11.1 1426±10.35 
Flux 
µg/hr/cm2 
11.25 16.06 12.05 
Kp(cmhr-
1X102) 
1.14±0.150  
 
1.63±0.0014 1.22±0.015 
Values represent mean ± SD (n=3) 
 
 
Figure 6:Comparison of cumulative drug permeated 
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CONCLUSION 
Matrix type transdermal therapeutic systems of TIZ HCl were 
prepared with the required flux having suitable mechanical 
properties. The T6 formulation has shown good in-vitro 
release of drug and therefore chosen for further studies for 
optimization of concentration of permeation enhancer. T6 
(14% citral) formulation showed higher flux than targeted 
flux. Hence TIZ HCl transdermal drug delivery system can be 
developed to administer TIZ HCl through transdermal route 
to human beings. 
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